Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 17Terminated 3Withdrawn 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Neoplasm Metastasis 1Lung Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Cyclophosphamide 128Cisplatin 119Radiotherapy 111pembrolizumab 110Paclitaxel 96Gemcitabine 96Carboplatin 96Nivolumab 76Magnetic Resonance Spectroscopy 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Doxorubicin 52fludarabine 51Biopsy 48durvalumab 44Cytarabine 44Drug Therapy 43Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Lenalidomide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Interventional × dalotuzumab × Clear all
NCT00951444 2016-07-06

Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01175291 2011-12-05

FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Withdrawn
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡